{"protocolSection": {"identificationModule": {"nctId": "NCT00687973", "orgStudyIdInfo": {"id": "CVAA489AFR02"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg", "officialTitle": "Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg", "acronym": "EXPLOR"}, "statusModule": {"statusVerifiedDate": "2011-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-01"}, "primaryCompletionDateStruct": {"date": "2009-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-03-20", "studyFirstSubmitQcDate": "2008-05-30", "studyFirstPostDateStruct": {"date": "2008-06-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-22", "resultsFirstSubmitQcDate": "2010-12-22", "resultsFirstPostDateStruct": {"date": "2011-01-21", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-03-08", "lastUpdatePostDateStruct": {"date": "2011-03-11", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Assess that for an equivalent brachial blood pressure (BP)lowering, a fixed dose combination amlodipine/valsartan based regimen reduces central aortic BP pressure to a larger extent than an atenolol/amlodipine combination based regimen."}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 393, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Valsartan/amlodipine 160/10 mg", "type": "EXPERIMENTAL", "description": "Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.", "interventionNames": ["Drug: Valsartan/amlodipine 80/5 mg tablets"]}, {"label": "Atenolol/amlodipine 100/10 mg", "type": "ACTIVE_COMPARATOR", "description": "Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.", "interventionNames": ["Drug: Amlodipine 5 mg capsules", "Drug: Amlodipine 10 mg capsules", "Drug: Atenolol 50 mg tablets", "Drug: Atenolol 100 mg tablets"]}], "interventions": [{"type": "DRUG", "name": "Valsartan/amlodipine 80/5 mg tablets", "armGroupLabels": ["Valsartan/amlodipine 160/10 mg"]}, {"type": "DRUG", "name": "Amlodipine 5 mg capsules", "armGroupLabels": ["Atenolol/amlodipine 100/10 mg"]}, {"type": "DRUG", "name": "Amlodipine 10 mg capsules", "armGroupLabels": ["Atenolol/amlodipine 100/10 mg"]}, {"type": "DRUG", "name": "Atenolol 50 mg tablets", "armGroupLabels": ["Atenolol/amlodipine 100/10 mg"]}, {"type": "DRUG", "name": "Atenolol 100 mg tablets", "armGroupLabels": ["Atenolol/amlodipine 100/10 mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 24 (Radial Measurement)", "timeFrame": "Baseline and Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 8 (Radial Measurement)", "timeFrame": "Baseline and Week 8"}, {"measure": "Change From Baseline of Central Pulse Pressure at Week 24 (Radial Measurement)", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline of Augmentation Index (Aix) at Week 8", "description": "To calculate the blood pressure augmentation index, the inflection point of the pressure curve corresponding to the return of the reflection wave was determined. The ratio between the pressure located above and below the inflection point was calculated.", "timeFrame": "Baseline and Week 8"}, {"measure": "Change From Baseline of Aix at Week 24", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline of Aix Corrected to Heart Rate at Week 24", "description": "The heart rate correction was computed by a multivariate model analysis", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline of Pulse Wave Velocity at Week 24 (Radial Measurement)", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline of Brachial SBP/DBP at Week 24 (Tonometry Center)", "description": "Applanation tonometry is a measurement of aortic pressure and vascular stiffness. To assess the central aortic blood pressure, it is necessary to calibrate the applanation tonometry device using the brachial blood pressure.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline of Brachial Pulse Pressure at Week 24 (Tonometry Center)", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline of SBP/DBP at Week 24 (Office BP)", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline of Pulse Pressure at Week 24 (Office BP)", "timeFrame": "Baseline and Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female patients 18 years of age or older\n* Hypertension defined by MSDBP \\> 90 and or MSSBP \\> 140 mmHg, MSDBP \\> 80 mmHg, or/and MSSBP \\> 130 mmHg if diabetes or chronic renal impairment uncontrolled under their previous therapy, or untreated , or experiencing unacceptable side effects\n* Written informed consent to participate in the study prior to any study procedures\n\nExclusion Criteria:\n\n* Severe hypertension (grade 3 WHO classification MSDBP \\> 110 mmHg and/or MSSBP \\> 180 mmHg)\n* Evidence of a secondary form of hypertension\n* Type 1 diabetes mellitus\n* History of congestive heart failure, unstable coronary insufficiency, life threatening arrhythmia, significant valvular disease, second or third degree heart block etc.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "2 & 4 rue Lionel Terray BP 308", "city": "Rueil-Malmaison", "zip": "92506", "country": "France", "geoPoint": {"lat": 48.8765, "lon": 2.18967}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Valsartan/Amlodipine 160/10 mg", "description": "Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}, {"id": "FG001", "title": "Atenolol/Amlodipine 100/10 mg", "description": "Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "193"}, {"groupId": "FG001", "numSubjects": "200"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "169"}, {"groupId": "FG001", "numSubjects": "162"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "38"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "28"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Administrative Reasons", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Valsartan/Amlodipine 160/10 mg", "description": "Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}, {"id": "BG001", "title": "Atenolol/Amlodipine 100/10 mg", "description": "Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "193"}, {"groupId": "BG001", "value": "200"}, {"groupId": "BG002", "value": "393"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57.5", "spread": "9.94"}, {"groupId": "BG001", "value": "56.2", "spread": "11.09"}, {"groupId": "BG002", "value": "56.9", "spread": "10.55"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "82"}, {"groupId": "BG001", "value": "101"}, {"groupId": "BG002", "value": "183"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "111"}, {"groupId": "BG001", "value": "99"}, {"groupId": "BG002", "value": "210"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "France", "categories": [{"measurements": [{"groupId": "BG000", "value": "193"}, {"groupId": "BG001", "value": "200"}, {"groupId": "BG002", "value": "393"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 24 (Radial Measurement)", "populationDescription": "Intent to treat (ITT) population; Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/10 mg", "description": "Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}, {"id": "OG001", "title": "Atenolol/Amlodipine 100/10 mg", "description": "Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "178"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.65", "spread": "1.15"}, {"groupId": "OG001", "value": "-9.7", "spread": "1.09"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 8 (Radial Measurement)", "populationDescription": "Intent to treat (ITT) population; Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/10 mg", "description": "Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}, {"id": "OG001", "title": "Atenolol/Amlodipine 100/10 mg", "description": "Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "183"}, {"groupId": "OG001", "value": "189"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.92", "spread": "1.18"}, {"groupId": "OG001", "value": "-8.3", "spread": "1.12"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of Central Pulse Pressure at Week 24 (Radial Measurement)", "populationDescription": "Intent to treat (ITT) population; Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/10 mg", "description": "Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}, {"id": "OG001", "title": "Atenolol/Amlodipine 100/10 mg", "description": "Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "178"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.5", "spread": "0.65"}, {"groupId": "OG001", "value": "-1.7", "spread": "0.63"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of Augmentation Index (Aix) at Week 8", "description": "To calculate the blood pressure augmentation index, the inflection point of the pressure curve corresponding to the return of the reflection wave was determined. The ratio between the pressure located above and below the inflection point was calculated.", "populationDescription": "Intent to treat (ITT) population; Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Ratio", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/10 mg", "description": "Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}, {"id": "OG001", "title": "Atenolol/Amlodipine 100/10 mg", "description": "Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}, {"groupId": "OG001", "value": "187"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.21", "spread": "0.78"}, {"groupId": "OG001", "value": "3.61", "spread": "0.76"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of Aix at Week 24", "populationDescription": "Intent to treat (ITT) population; Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Ratio", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/10 mg", "description": "Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}, {"id": "OG001", "title": "Atenolol/Amlodipine 100/10 mg", "description": "Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "175"}, {"groupId": "OG001", "value": "178"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.10", "spread": "0.72"}, {"groupId": "OG001", "value": "2.40", "spread": "0.70"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of Aix Corrected to Heart Rate at Week 24", "description": "The heart rate correction was computed by a multivariate model analysis", "populationDescription": "Intent to treat (ITT) population; Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Ratio", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/10 mg", "description": "Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}, {"id": "OG001", "title": "Atenolol/Amlodipine 100/10 mg", "description": "Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "169"}, {"groupId": "OG001", "value": "170"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.12", "spread": "0.67"}, {"groupId": "OG001", "value": "-2.43", "spread": "0.66"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of Pulse Wave Velocity at Week 24 (Radial Measurement)", "populationDescription": "Intent to treat (ITT) population; Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "m/s", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/10 mg", "description": "Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}, {"id": "OG001", "title": "Atenolol/Amlodipine 100/10 mg", "description": "Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "139"}, {"groupId": "OG001", "value": "147"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.98", "spread": "0.18"}, {"groupId": "OG001", "value": "-0.95", "spread": "0.17"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of Brachial SBP/DBP at Week 24 (Tonometry Center)", "description": "Applanation tonometry is a measurement of aortic pressure and vascular stiffness. To assess the central aortic blood pressure, it is necessary to calibrate the applanation tonometry device using the brachial blood pressure.", "populationDescription": "ITT population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/10 mg", "description": "Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}, {"id": "OG001", "title": "Atenolol/Amlodipine 100/10 mg", "description": "Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "176"}]}], "classes": [{"title": "SBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-12.93", "spread": "1.14"}, {"groupId": "OG001", "value": "-11.78", "spread": "1.11"}]}]}, {"title": "DBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.85", "spread": "0.70"}, {"groupId": "OG001", "value": "-7.94", "spread": "0.68"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of Brachial Pulse Pressure at Week 24 (Tonometry Center)", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/10 mg", "description": "Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}, {"id": "OG001", "title": "Atenolol/Amlodipine 100/10 mg", "description": "Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "176"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.02", "spread": "0.72"}, {"groupId": "OG001", "value": "-3.66", "spread": "0.70"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of SBP/DBP at Week 24 (Office BP)", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/10 mg", "description": "Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}, {"id": "OG001", "title": "Atenolol/Amlodipine 100/10 mg", "description": "Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "183"}, {"groupId": "OG001", "value": "185"}]}], "classes": [{"title": "SBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.49", "spread": "1.08"}, {"groupId": "OG001", "value": "-16.94", "spread": "1.07"}]}]}, {"title": "DBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.17", "spread": "0.72"}, {"groupId": "OG001", "value": "-10.45", "spread": "0.71"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of Pulse Pressure at Week 24 (Office BP)", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/10 mg", "description": "Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}, {"id": "OG001", "title": "Atenolol/Amlodipine 100/10 mg", "description": "Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "183"}, {"groupId": "OG001", "value": "185"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.32", "spread": "0.81"}, {"groupId": "OG001", "value": "-6.48", "spread": "0.81"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Amlodipine 5 mg", "description": "Run-in: Amlodipine 5 mg", "seriousNumAffected": 3, "seriousNumAtRisk": 393, "otherNumAffected": 10, "otherNumAtRisk": 393}, {"id": "EG001", "title": "Valsartan/Amlodipine 160/10 mg", "description": "Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.", "seriousNumAffected": 4, "seriousNumAtRisk": 193, "otherNumAffected": 30, "otherNumAtRisk": 193}, {"id": "EG002", "title": "Atenolol/Amlodipine 100/10 mg", "description": "Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.", "seriousNumAffected": 4, "seriousNumAtRisk": 200, "otherNumAffected": 31, "otherNumAtRisk": 200}], "seriousEvents": [{"term": "Colitis ulcerative", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 393}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 193}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 200}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 393}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 193}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 200}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 393}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 193}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 200}]}, {"term": "Lip and/or oral cavity cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 393}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 193}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 200}]}, {"term": "Neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 393}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 193}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 200}]}, {"term": "Pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 393}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 193}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 200}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 393}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 193}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 200}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 393}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 193}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 200}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 393}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 193}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 200}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 393}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 193}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 200}]}, {"term": "Cholecystectomy", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 393}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 193}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 200}]}, {"term": "Cyst removal", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 393}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 193}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 200}]}, {"term": "Inguinal hernia repair", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 393}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 193}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 200}]}, {"term": "Joint arthroplasty", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 393}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 193}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 200}]}], "otherEvents": [{"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 393}, {"groupId": "EG001", "numAffected": 30, "numAtRisk": 193}, {"groupId": "EG002", "numAffected": 31, "numAtRisk": 200}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However,Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862 778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000001262", "term": "Atenolol"}, {"id": "D000017311", "term": "Amlodipine"}, {"id": "D000068756", "term": "Valsartan"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000013565", "term": "Sympatholytics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000058671", "term": "Adrenergic beta-1 Receptor Antagonists"}, {"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M4568", "name": "Atenolol", "asFound": "Allowing", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M16344", "name": "Sympatholytics", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M29197", "name": "Adrenergic beta-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}